Pawsey S, Mills EG, Ballantyne E, et al. - Since the integrated neurokinin-kisspeptin system involving Substance P and neurokinin B acting at the neurokinin (NK) receptors 1 and 3, respectively, modulates reproductive hormone secretion and represents a therapeutic target, researchers conducted this randomized, single-blinded, placebo-controlled study to evaluate the impacts of the novel NK1,3 antagonist elinzanetant on reproductive hormone levels in healthy women. Thirty-three women participated in two consecutive menstrual cycles. In healthy women, NK1,3 receptor antagonism with elinzanetant suppressed the reproductive axis in a dose-dependent manner, with the 120 mg dose reducing estradiol to potentially ideal levels for uterine fibroids and endometriosis. As such, elinzanetant may be a novel therapy for the manipulation of reproductive hormone levels in women with hormonal disorders.